576 related articles for article (PubMed ID: 30287935)
1. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
Harms PW; Harms KL; Moore PS; DeCaprio JA; Nghiem P; Wong MKK; Brownell I;
Nat Rev Clin Oncol; 2018 Dec; 15(12):763-776. PubMed ID: 30287935
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
4. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
5. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
6. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
7. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
8. Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.
Gavvovidis I; Leisegang M; Willimsky G; Miller N; Nghiem P; Blankenstein T
Clin Cancer Res; 2018 Aug; 24(15):3644-3655. PubMed ID: 29669806
[No Abstract] [Full Text] [Related]
9. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
10. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
13. Decreased H3K27me3 Expression Is Associated With Merkel Cell Polyomavirus-negative Merkel Cell Carcinoma, Especially Combined With Cutaneous Squamous Cell Carcinoma.
Matsushita M; Iwasaki T; Wardhani LO; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
Anticancer Res; 2019 Oct; 39(10):5573-5579. PubMed ID: 31570452
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Marchand A; Kervarrec T; Bhatia S; Samimi M
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
[TBL] [Abstract][Full Text] [Related]
15. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
[TBL] [Abstract][Full Text] [Related]
16. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
17. Current concepts and approaches to merkel cell carcinoma.
Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
[TBL] [Abstract][Full Text] [Related]
18. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
19. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
20. Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma.
Nakamura M; Nagase K; Yoshimitsu M; Magara T; Nojiri Y; Kato H; Kobayashi T; Teramoto Y; Yasuda M; Wada H; Ozawa T; Umemori Y; Ogata D; Morita A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
